Sudden Infant Death Syndrome
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Human BioSciencesWV - Martinsburg
2 programsIncidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for N/A1 trial
Safe Sleep InterventionN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Human BioSciencesSafe Sleep Intervention
Human BioSciencesIncidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for
Clinical Trials (2)
Total enrollment: 1,114 patients across 2 trials
Enhancing Safe Sleep Practices of Urban Low-Income Mothers
Start: Oct 2015Est. completion: Jun 2017214 patients
N/ACompleted
NCT00004392Human BioSciencesIncidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for
Incidence and Severity of Cardiorespiratory Events in Infants at Increased Epidemiological Risk for Sudden Infant Death Syndrome (SIDS)
Start: May 1994Est. completion: Aug 1999900 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.